PATIENT STORIES: THE USE OF NOVEL ANTI-FIBROTICS, PIRFENIDONE AND NINTEDANIB, IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS, IPF

被引：0
|
作者：
Enston-Newall, S. [1 ]
机构：
[1] Cardiff Univ, Cardiff, S Glam, Wales
来源：
THORAX | 2017年 / 72卷
关键词：
D O I：
10.1136/thoraxjnl-2017-210983.443
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
M21
引用
收藏
页码：A247 / A248
页数：2
相关论文
共 50 条
  • [1] Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis
    Funke-Chambour, Manuela
    Geiser, Thomas
    THERAPEUTISCHE UMSCHAU, 2016, 73 (01) : 25 - 29
  • [2] Mortality Effect of the Anti-Fibrotics Pirfenidone and Nintedanib in Clinical Practice
    Dempsey, T. M.
    Sangaralingham, L.
    Yao, X.
    Limper, A. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [3] Pre-transplant anti-fibrotics for idiopathic pulmonary fibrosis: Are we seeing a new role for the anti-fibrotics?
    Prasad, Jyotika D.
    Snell, Gregory I.
    RESPIROLOGY, 2024, 29 (01) : 16 - 17
  • [4] Safety of Combined Pirfenidone and Nintedanib in Subgroups of Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Flaherty, K.
    Fell, C. D.
    Huggins, J. T.
    Nunes, H.
    Sussman, R.
    Valenzuela, C.
    Petzinger, U.
    Stauffer, J. L.
    Gilberg, F.
    Bengus, M.
    Wijsenbeek, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [5] The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
    Wijsenbeek-Lourens, Marlies S.
    Kimman, Merel L.
    Rotteveel, Adrienne
    van Jaarsveld, Xana
    Weinreich, Stephanie S.
    Mostard, Remy
    Dirksen, Carmen D.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [6] A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
    Naqvi, Marium
    D'Ancona, Grainne
    West, Alex
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [7] Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
    Dempsey, Timothy M.
    Thao, Viengneesee
    Moriarty, James P.
    Borah, Bijan J.
    Limper, Andrew H.
    BMC PULMONARY MEDICINE, 2022, 22 (01)
  • [8] Prescription Of Pirfenidone And Nintedanib For The Treatment Of Idiopathic Pulmonary Fibrosis (ipf): An Academic Center Experience
    Strock, S.
    Nouraie, S. M.
    Huttenhower, D.
    Chen, X.
    Lawson, K.
    Priore, M. Melissa
    Chiarchiaro, J.
    Veraldi, K. L.
    Lindell, K. O.
    Gibson, K. F.
    Kass, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [9] Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
    Timothy M. Dempsey
    Viengneesee Thao
    James P. Moriarty
    Bijan J. Borah
    Andrew H. Limper
    BMC Pulmonary Medicine, 22
  • [10] HEPATIC DISORDERS OF PIRFENIDONE OR NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) A SYSTEMATIC REVIEW
    Singla, D.
    Mahapatra, S.
    Dey, A.
    John, A.
    VALUE IN HEALTH, 2022, 25 (12) : S218 - S218
12345